Evidence map›Paper›PMID 34671771›Full record

ArticlebioRxiv : the preprint server for biology2022

Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis.

Bryan A Johnson, Yiyang Zhou, Kumari G Lokugamage, Michelle N Vu, Nathen Bopp, Patricia A Crocquet-Valdes, Birte Kalveram, Craig Schindewolf, Yang Liu, Dionna Scharton and 9 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 25 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Bryan A JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Yiyang ZhouDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Kumari G LokugamageDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Michelle N VuDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Nathen BoppDepartment of Pathology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Patricia A Crocquet-ValdesDepartment of Pathology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Birte KalveramDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Craig SchindewolfDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Yang LiuDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Dionna SchartonDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Jessica A PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Patricia AguilarDepartment of Pathology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch; Galveston, Texas, United States of America.
David H WalkerDepartment of Pathology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Andrew L RouthDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Kenneth S PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Galveston College · US

Funding

World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
EMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
NIAID NIH HHS R01 AI153602
6 · The paper itself

Abstract

While SARS-CoV-2 continues to adapt for human infection and transmission, genetic variation outside of the spike gene remains largely unexplored. This study investigates a highly variable region at residues 203-205 in the SARS-CoV-2 nucleocapsid protein. Recreating a mutation found in the alpha and omicron variants in an early pandemic (WA-1) background, we find that the R203K+G204R mutation is sufficient to enhance replication, fitness, and pathogenesis of SARS-CoV-2. The R203K+G204R mutant corresponds with increased viral RNA and protein both AUTHOR SUMMARY: Since its emergence, SARS-CoV-2 has continued to adapt for human infection resulting in the emergence of variants with unique genetic profiles. Most studies of genetic variation have focused on spike, the target of currently available vaccines, leaving the importance of variation elsewhere understudied. Here, we characterize a highly variable motif at residues 203-205 in nucleocapsid. Recreating the prominent nucleocapsid R203K+G204R mutation in an early pandemic background, we show that this mutation is alone sufficient to enhance SARS-CoV-2 replication and pathogenesis. We also link augmentation of SARS-CoV-2 infection by the R203K+G204R mutation to its modulation of nucleocapsid phosphorylation. Finally, we characterize an analogous alanine double substitution at positions 203-204. This mutant was found to mimic R203K+G204R, suggesting augmentation of infection occurs by disrupting the ancestral sequence. Together, our findings illustrate that mutations outside of spike are key components of SARS-CoV-2's adaptation to human infection.

Identifiers

PMID34671771
PMCPMC8528077
OpenAlexW3207928276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.